Italia markets closed

Novo Nordisk A/S (NONOF)

Other OTC - Other OTC Prezzo differito. Valuta in USD.
Aggiungi a watchlist
101,50-0,90 (-0,88%)
Alla chiusura: 03:58PM EST
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente102,40
Denaro0,00 x 0
Lettera0,00 x 0
Min-Max giorno99,64 - 103,85
Intervallo di 52 settimane61,62 - 108,51
Media Volume20.339
Beta (5 anni mensile)0,20
Rapporto PE (ttm)41,43
EPS (ttm)2,45
Prossima data utiliN/D
Rendimento e dividendo (futuro)1,03 (1,01%)
Data ex dividendo18 ago 2023
Stima target 1AN/D
  • GlobeNewswire

    Novo Nordisk A/S – Share repurchase programme

    Bagsværd, Denmark, 16 October 2023 – On 10 August 2023, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 30 billion to be executed during a 12-month period beginning 1 February 2023. Under the programme

  • GlobeNewswire

    Novo Nordisk to acquire ocedurenone for uncontrolled hypertension from KBP Biosciences

    Bagsværd, Denmark and Singapore, 16 October 2023 – Novo Nordisk A/S and KBP Biosciences PTE., Ltd. today announced that Novo Nordisk has agreed to acquire ocedurenone for uncontrolled hypertension with potential application in cardiovascular and kidney disease from KBP Biosciences for up to 1.3 billion US dollars. Ocedurenone is an orally administered, small molecule, non-steroidal mineralocorticoid receptor antagonist (nsMRA) that is currently being examined in the phase 3 trial CLARION-CKD in

  • FX Empire

    Novo Nordisk: Relentless Inflows Send Shares Soaring

    Novo Nordisk (NVO) shares are surging, up 51% in 2023. While the company recently raised its guidance due to Ozempic and Wegovy, mega demand for the stock is powering the surge.